FDA 510(k) RESCISSION POLICY WILL BE CHALLENGED BY HIMA
This article was originally published in The Gray Sheet
Executive SummaryFDA 510(k) RESCISSION POLICY WILL BE CHALLENGED BY HIMA in a petition under development, the Health Industry Manufacturers Association says in an "Action Plan on FDA Compliance and Enforcement" released the week of Aug. 1. The citizen's petition, which has already been drafted, is under review by HIMA committees including its enforcement and product approval task forces.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.